Rituximab

From the Field

Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab

04/20/2022

Erica DiMaria , MD;

David Susman ;

Derek Nay , MD;

Rouslan Kotchetkov , MD, PhD;

Lauren Gerard , MD;

Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.

Dr Kotchetkov and colleagues...

04/20/2022

Journal of Clinical Pathways

Videos

Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice

01/14/2021

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

See Full Calendar

Rituximab

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products